{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T23:19:28Z","timestamp":1788477568742,"version":"build-2803163510"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"vor","delay-in-days":79,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-56672-6","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T11:54:12Z","timestamp":1781697252000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic value of systemic inflammatory markers in avelumab maintenance for advanced urothelial carcinoma: the multicentric SAILOR analysis"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5423-3158","authenticated-orcid":false,"given":"Brigida Anna","family":"Maiorano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giandomenico","family":"Roviello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Ciccimarra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Maruzzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Pierantoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Messina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Messina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Fanelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonello","family":"Veccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mimma","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Cavo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenza","family":"Conteduca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo Emanuele","family":"Chiuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Cerbone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Roberto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Paolieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Galanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gian Paolo","family":"Spinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Mennitto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Pisino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Filippi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Guadalupi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Cossu","family":"Rocca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierangela","family":"Sepe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Palma","family":"Fedele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Dionese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Secondino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara Elena","family":"Rebuzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Vignani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariella","family":"Sorar\u00f9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Doronzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Catalano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Gambale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Santini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Santoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Di Maio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Antonuzzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Necchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,17]]},"reference":[{"key":"56672_CR1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel, R. L., Giaquinto, A. N. & Jemal, A. Cancer statistics, 2024. CA Cancer J. Clin. 74, 12\u201349. https:\/\/doi.org\/10.3322\/caac.21820 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"56672_CR2","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","volume":"383","author":"T Powles","year":"2020","unstructured":"Powles, T. et al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N Engl. J. Med. 383, 1218\u20131230. https:\/\/doi.org\/10.1056\/NEJMoa2002788 (2020).","journal-title":"N Engl. J. Med."},{"key":"56672_CR3","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.annonc.2021.11.012","volume":"33","author":"T Powles","year":"2022","unstructured":"Powles, T. et al. Bladder cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann. Oncol. 33, 244\u2013258. https:\/\/doi.org\/10.1016\/j.annonc.2021.11.012 (2022).","journal-title":"Ann. Oncol."},{"issue":"1","key":"56672_CR4","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s40425-018-0314-1","volume":"6","author":"J Zhu","year":"2018","unstructured":"Zhu, J. et al. Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond. J. Immunother. Cancer 6 (1), 4. https:\/\/doi.org\/10.1186\/s40425-018-0314-1 (2018).","journal-title":"J. Immunother Cancer"},{"issue":"3","key":"56672_CR5","doi-asserted-by":"publisher","first-page":"e241215","DOI":"10.1001\/jamanetworkopen.2024.1215","volume":"7","author":"BA Maiorano","year":"2024","unstructured":"Maiorano, B. A. et al. Significance of PD-L1 in metastatic urothelial carcinoma treated with immune checkpoint inhibitors: A systematic review and meta-analysis. JAMA Netw. Open. 7 (3), e241215. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.1215 (2024).","journal-title":"JAMA Netw. Open."},{"key":"56672_CR6","doi-asserted-by":"publisher","first-page":"104862","DOI":"10.1016\/j.critrevonc.2025.104862","volume":"215","author":"M Ferro","year":"2025","unstructured":"Ferro, M. et al. Emerging biomarkers in bladder cancer: Translating molecular advances into precision oncology. Crit. Rev. Oncol. Hematol. 215, 104862. https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104862 (2025).","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"3","key":"56672_CR7","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/j.euo.2024.11.008","volume":"8","author":"M Garofoli","year":"2025","unstructured":"Garofoli, M. et al. Circulating tumor DNA: A new research frontier in urological oncology from localized to metastatic disease. Eur. Urol. Oncol. 8 (3), 805\u2013817. https:\/\/doi.org\/10.1016\/j.euo.2024.11.008 (2025).","journal-title":"Eur. Urol. Oncol."},{"key":"56672_CR8","doi-asserted-by":"publisher","unstructured":"Powles, T. et al. IMvigor011 Investigators. ctDNA-guided adjuvant atezolizumab in muscle-invasive bladder cancer. N Engl. J. Med. 393 (24):2395\u20132408. https:\/\/doi.org\/10.1056\/NEJMoa2511885 (2025).","DOI":"10.1056\/NEJMoa2511885"},{"key":"56672_CR9","doi-asserted-by":"publisher","unstructured":"Galsky, M. D. et al. Adjuvant nivolumab versus placebo for high-risk muscle-invasive urothelial carcinoma: 5-year efficacy and ctDNA results from CheckMate 274. Ann Oncol. S0923-7534(25)04930-0. https:\/\/doi.org\/10.1016\/j.annonc.2025.09.139 (2025).","DOI":"10.1016\/j.annonc.2025.09.139"},{"key":"56672_CR10","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","volume":"12","author":"D Hanahan","year":"2022","unstructured":"Hanahan, D. Hallmarks of cancer: New dimensions. Cancer Discov. 12, 31\u201346. https:\/\/doi.org\/10.1158\/2159-8290.CD-21-1059 (2022).","journal-title":"Cancer Discov"},{"key":"56672_CR11","doi-asserted-by":"publisher","unstructured":"Chen, X., Meng, F. & Jiang, R. Neutrophil-to-lymphocyte ratio as a prognostic biomarker for patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors: A systematic review and meta-analysis. Front. Oncol. 11. https:\/\/doi.org\/10.3389\/fonc.2021.746976 (2021).","DOI":"10.3389\/fonc.2021.746976"},{"key":"56672_CR12","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.lungcan.2017.07.024","volume":"111","author":"S Diem","year":"2017","unstructured":"Diem, S. et al. Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. Lung Cancer 111, 176\u2013181. https:\/\/doi.org\/10.1016\/j.lungcan.2017.07.024 (2017).","journal-title":"Lung Cancer"},{"key":"56672_CR13","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1038\/bjc.2015.180","volume":"112","author":"PF Ferrucci","year":"2015","unstructured":"Ferrucci, P. F. et al. Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients. Br. J. Cancer 112, 1904\u20131910. https:\/\/doi.org\/10.1038\/bjc.2015.180 (2015).","journal-title":"Br. J. Cancer"},{"key":"56672_CR14","doi-asserted-by":"publisher","unstructured":"Guida, M. et al. Basal and one-month differed neutrophil, lymphocyte and platelet values and their ratios strongly predict the efficacy of checkpoint inhibitors immunotherapy in patients with advanced BRAF wild-type melanoma. J. Transl. Med. 20. https:\/\/doi.org\/10.1186\/s12967-022-03359-x (2022).","DOI":"10.1186\/s12967-022-03359-x"},{"key":"56672_CR15","doi-asserted-by":"publisher","first-page":"100118","DOI":"10.1016\/j.esmoop.2021.100118","volume":"6","author":"G Fornarini","year":"2021","unstructured":"Fornarini, G. et al. Immune-inflammatory biomarkers as prognostic factors for immunotherapy in pretreated advanced urinary tract cancer patients: An analysis of the Italian SAUL cohort. ESMO Open 6, 100118. https:\/\/doi.org\/10.1016\/j.esmoop.2021.100118 (2021).","journal-title":"ESMO Open."},{"key":"56672_CR16","doi-asserted-by":"publisher","first-page":"4236","DOI":"10.1002\/cam4.4779","volume":"11","author":"Y Miyama","year":"2022","unstructured":"Miyama, Y., Kaneko, G., Nishimoto, K. & Yasuda, M. Lower neutrophil-to\u2010lymphocyte ratio and positive programmed cell death ligand\u20101 expression are favorable prognostic markers in patients treated with pembrolizumab for urothelial carcinoma. Cancer Med. 11, 4236\u20134245. https:\/\/doi.org\/10.1002\/cam4.4779 (2022).","journal-title":"Cancer Med."},{"key":"56672_CR17","doi-asserted-by":"publisher","first-page":"310","DOI":"10.3390\/diagnostics10050310","volume":"10","author":"T Shimizu","year":"2020","unstructured":"Shimizu, T. et al. Clinical Impact of Sarcopenia and Inflammatory\/Nutritional Markers in Patients with Unresectable Metastatic Urothelial Carcinoma Treated with Pembrolizumab. Diagnostics 10, 310. https:\/\/doi.org\/10.3390\/diagnostics10050310 (2020).","journal-title":"Diagnostics"},{"key":"56672_CR18","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1007\/s10147-021-01936-6","volume":"26","author":"D Tural","year":"2021","unstructured":"Tural, D. et al. Prognostic factors in patients with metastatic urothelial carcinoma who have treated with Atezolizumab. Int. J. Clin. Oncol. 26, 1506\u20131513. https:\/\/doi.org\/10.1007\/s10147-021-01936-6 (2021).","journal-title":"Int. J. Clin. Oncol."},{"key":"56672_CR19","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s10147-020-01784-w","volume":"26","author":"Y Yamamoto","year":"2021","unstructured":"Yamamoto, Y. et al. Prognostic value of pre-treatment risk stratification and post-treatment neutrophil\/lymphocyte ratio change for pembrolizumab in patients with advanced urothelial carcinoma. Int. J. Clin. Oncol. 26, 169\u2013177. https:\/\/doi.org\/10.1007\/s10147-020-01784-w (2021).","journal-title":"Int. J. Clin. Oncol."},{"key":"56672_CR20","doi-asserted-by":"publisher","first-page":"1401214","DOI":"10.3389\/fimmu.2024.1401214","volume":"15","author":"BA Maiorano","year":"2024","unstructured":"Maiorano, B. A. et al. Prognostic role of circulating cytokines and inflammation indexes for avelumab maintenance in metastatic urothelial carcinoma. Front. Immunol. 15, 1401214. https:\/\/doi.org\/10.3389\/fimmu.2024.1401214 (2024).","journal-title":"Front. Immunol."},{"issue":"9596","key":"56672_CR21","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","volume":"370","author":"E von Elm","year":"2007","unstructured":"von Elm, E. et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE)statement: Guidelines for reporting observational studies. Lancet 370 (9596), 1453\u20131457. https:\/\/doi.org\/10.1016\/S0140-6736(07)61602-X (2007).","journal-title":"Lancet"},{"key":"56672_CR22","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s40425-018-0383-1","volume":"6","author":"M Capone","year":"2018","unstructured":"Capone, M. et al. Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab. J. Immunotherapy Cancer 6, 74. https:\/\/doi.org\/10.1186\/s40425-018-0383-1 (2018).","journal-title":"j. immunotherapy cancer"},{"key":"56672_CR23","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1093\/annonc\/mdw016","volume":"27","author":"PF Ferrucci","year":"2016","unstructured":"Ferrucci, P. F. et al. Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: Prognostic relevance in metastatic melanoma patients receiving ipilimumab. Ann. Oncol. 27, 732\u2013738. https:\/\/doi.org\/10.1093\/annonc\/mdw016 (2016).","journal-title":"Ann. Oncol."},{"key":"56672_CR24","doi-asserted-by":"publisher","first-page":"5297","DOI":"10.3390\/cancers14215297","volume":"14","author":"Y Guo","year":"2022","unstructured":"Guo, Y., Xiang, D., Wan, J., Yang, L. & Zheng, C. Focus on the dynamics of neutrophil-to-lymphocyte ratio in cancer patients treated with immune checkpoint inhibitors: A meta-analysis and systematic review. Cancers 14, 5297. https:\/\/doi.org\/10.3390\/cancers14215297 (2022).","journal-title":"Cancers"},{"key":"56672_CR25","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1159\/000489152","volume":"46","author":"S Wu","year":"2018","unstructured":"Wu, S. et al. Pretreatment neutrophil-lymphocyte ratio as a predictor in bladder cancer and metastatic or unresectable urothelial carcinoma patients: A pooled analysis of comparative studies. Cell. Physiol. Biochem. 46, 1352\u20131364. https:\/\/doi.org\/10.1159\/000489152 (2018).","journal-title":"Cell. Physiol. Biochem."},{"key":"56672_CR26","doi-asserted-by":"publisher","first-page":"602e1","DOI":"10.1016\/j.urolonc.2020.02.005","volume":"38","author":"K Ogihara","year":"2020","unstructured":"Ogihara, K. et al. The pretreatment neutrophil-to-lymphocyte ratio is a novel biomarker for predicting clinical responses to pembrolizumab in platinum-resistant metastatic urothelial carcinoma patients. Urol. Oncol. Sem. Orig. Invest. 38, 602e1\u2013602e10. https:\/\/doi.org\/10.1016\/j.urolonc.2020.02.005 (2020).","journal-title":"Urologic Oncology: Seminars Original Investigations"},{"key":"56672_CR27","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1007\/s10147-019-01613-9","volume":"25","author":"D Tamura","year":"2020","unstructured":"Tamura, D. et al. Prognostic outcomes and safety in patients treated with pembrolizumab for advanced urothelial carcinoma: Experience in real-world clinical practice. Int. J. Clin. Oncol. 25, 899\u2013905. https:\/\/doi.org\/10.1007\/s10147-019-01613-9 (2020).","journal-title":"Int. J. Clin. Oncol."},{"key":"56672_CR28","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s12943-024-02004-z","volume":"23","author":"X Huang","year":"2024","unstructured":"Huang, X. et al. Neutrophils in cancer immunotherapy: Friends or foes? Mol. Cancer. 23, 107. https:\/\/doi.org\/10.1186\/s12943-024-02004-z (2024).","journal-title":"Mol. Cancer"},{"key":"56672_CR29","doi-asserted-by":"publisher","first-page":"1601773","DOI":"10.3389\/fimmu.2025.1601773","volume":"16","author":"FP Kraja","year":"2025","unstructured":"Kraja, F. P. et al. Tumor-infiltrating lymphocytes in cancer immunotherapy: From chemotactic recruitment to translational modeling. Front. Immunol. 16, 1601773. https:\/\/doi.org\/10.3389\/fimmu.2025.1601773 (2025).","journal-title":"Front. Immunol."},{"key":"56672_CR30","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.3390\/cells12131673","volume":"12","author":"X Chen","year":"2023","unstructured":"Chen, X., Li, Y., Xia, H. & Chen, Y. H. Monocytes in tumorigenesis and tumor immunotherapy. Cells 12, 1673. https:\/\/doi.org\/10.3390\/cells12131673 (2023).","journal-title":"Cells"},{"key":"56672_CR31","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.21873\/anticanres.16966","volume":"44","author":"N Furubayashi","year":"2024","unstructured":"Furubayashi, N. et al. Change in the neutrophil-to-eosinophil ratio after avelumab maintenance for advanced urothelial carcinoma: The UROKYU study. Anticancer Res. 44, 1675\u20131681. https:\/\/doi.org\/10.21873\/anticanres.16966 (2024).","journal-title":"Anticancer Res."},{"key":"56672_CR32","doi-asserted-by":"publisher","first-page":"102099","DOI":"10.1016\/j.clgc.2024.102099","volume":"22","author":"E Gambale","year":"2024","unstructured":"Gambale, E. et al. Neutrophil-to-eosinophil ratio predicts the efficacy of avelumab in patients with advanced urothelial carcinoma enrolled in the MALVA study (Meet-URO 25). Clin. Genitourin. Cancer 22, 102099. https:\/\/doi.org\/10.1016\/j.clgc.2024.102099 (2024).","journal-title":"Clin. Genitourin. Cancer"},{"key":"56672_CR33","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1186\/s12967-023-04418-7","volume":"21","author":"S Ghaffari","year":"2023","unstructured":"Ghaffari, S. & Rezaei, N. Eosinophils in the tumor microenvironment: Implications for cancer immunotherapy. J. Transl. Med. 21, 551. https:\/\/doi.org\/10.1186\/s12967-023-04418-7 (2023).","journal-title":"J. Transl Med."},{"issue":"5","key":"56672_CR34","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.eururo.2025.02.019","volume":"87","author":"AG van der Heijden","year":"2025","unstructured":"van der Heijden, A. G. et al. European association of urology guidelines on muscle-invasive and metastatic bladder cancer: Summary of the 2025 guidelines. Eur. Urol. 87 (5), 582\u2013600. https:\/\/doi.org\/10.1016\/j.eururo.2025.02.019 (2025).","journal-title":"Eur. Urol."},{"key":"56672_CR35","doi-asserted-by":"publisher","first-page":"3295","DOI":"10.7150\/jca.25691","volume":"9","author":"R Yang","year":"2018","unstructured":"Yang, R., Chang, Q., Meng, X., Gao, N. & Wang, W. Prognostic value of systemic immune-inflammation index in cancer: A meta-analysis. J. Cancer 9, 3295\u20133302. https:\/\/doi.org\/10.7150\/jca.25691 (2018).","journal-title":"J. Cancer"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-56672-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-56672-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-56672-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T22:53:22Z","timestamp":1788476002000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-56672-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,17]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["56672"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-56672-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,17]]},"assertion":[{"value":"21 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"These authors declare the following disclosures: BAM: consultant\/advisory board role for Johnson&Johnson, Astellas, Bayer, Merck, Ipsen; speaker honoraria or travel support from Astellas, Bayer, BMS, Janssen, Ipsen, Merck. AC: consultant\/advisory board role for Johnson & Johnson, Astellas and Bayer. VC: consultant\/advisory board role for Johnson & Johnson, Astellas, Merck, AstraZeneca, Amgen, Eisai, Recordati, Novartis, Ipsen, and Bayer; and speaker honoraria or travel support from Astellas, Janssen, Ipsen, Bayer, Gilead, Novartis, and Bristol-Myers Squibb. VEC: consultant\/advisory board: Astellas, Eisai, Bayer; speaker honoraria or travel support: Astellas, Johnson & Johnson\/Janssen, Gilead, Gentili, Bayer, Amgen, Novartis. GPS: consultant\/advisory board role for Johnson & Johnson, Astellas, Novartis, Roche and Bayer. MDM: Financial - Amgen, Advisory Board, Personal, Advisory board about treatment of gastric cancer; Astellas, Advisory Board, Personal; AstraZeneca, Advisory Board, Personal, Consultancy about role of osimertinib as adjuvant treatment of NSCLC; Daiichi Sankio, Advisory Board, Personal, Advisory board about trastuzumab deruxtecan in gastric cancer; GlaxoSmithKline, Advisory Board, Personal, Lesson for the personnel of the drug company about quality of life, patient-reported outcomes and methodological aspects of clinical trials; Janssen, Advisory Board, Personal, Advisory board about the role of chemotherapy and hormonal treatment in hormone-sensitive prostate cancer; Merck Serono, Advisory Board, Personal, Consultant for the new indication of avelumab in urothelial cancer; Merck Sharp & Dohme, Advisory Board, Personal, Participation in advisory boards about olaparib in pancreatic cancer, about olaparib in prostate cancer, and about immunotherapy in lung cancer; Novartis, Advisory Board, Personal, Consultancy about clinical trial methodology and clinical trial results interpretation; Takeda, Advisory Board, Personal, Consultancy about role and interpretation of patient-reported outcomes and quality of life in clinical trials; Viatris, Advisory Board, Personal, Advisory board about Moovcare and remote monitoring of symptoms in patients with cancer; Beigene, Local PI, Institutional, Financial interest, Local PI of trial with tislelizumab in hepatocellular carcinoma; Exelixis, Local PI, Institutional, Financial interest, Local PI of a trial with cabozantinib and atezolizumab in advanced HCC; Merck Sharp & Dohme, Local PI, Institutional, Financial interest, Local PI of trials with pembrolizumab in hepatocellular carcinoma; Pfizer, Local PI, Institutional, Financial interest, Local PI of a trial with sasanlimab in NMI bladder cancer; Roche, Local PI, Institutional, Financial interest, Local PI of a trial with atezolizumab and bevacizumab in advanced HCC; Tesaro - GlaxoSmithKline, Research Grant, Institutional, Financial interest, Financial support and drug supply for the Meet-URO12 trial (niraparib as maintenance treatment of urothelial carcinoma after first-line treatment with platinum-based chemotherapy); Non-Financial Interests - AIOM (Italian Association of Medical Oncology), Leadership Role, President Elect (2023-2025).","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"27711"}}